Future Outlook in Front-line Treatment for uHCC.

James J. Harding, MD, discusses the remaining unmet needs in the first-line (1L) treatment space for unresectable hepatocellular carcinoma (uHCC) and how 1L immunotherapy (IO) combinations like nivolumab plus ipilimumab (NIVO + IPI) may help address these gaps, while highlighting unanswered questions and offering clinical pearls for managing uHCC.

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

EP: 3.Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

EP: 4.Navigating Between Front-line Systemic Therapies in uHCC.

EP: 5.Patient Considerations for Front-line Systemic Immunotherapies in uHCC.

Now Viewing

EP: 6.Future Outlook in Front-line Treatment for uHCC.

Video content above is prompted by the following:

• What are some remaining unmet needs in the 1L space for uHCC?
  • How will 1L IO combinations like NIVO + IPI in uHCC continue to address these gaps?
  • What remains unanswered?
  • Are there any clinical pearls to share?

Recent Videos